Two Sigma Securities’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Two Sigma Securities’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,461	Closed	-$243K	–	1556
2021 Q2	$243K	Buy	+2,461	New	+$215K	0.01%	1147
2017 Q3	–	Sell	-5,559	Closed	-$297K	–	931
2017 Q2	$297K	Buy	+5,559	New	+$271K	0.06%	366
2016 Q3	–	Sell	-5,365	Closed	-$208K	–	660
2016 Q2	$208K	Buy	+5,365	New	+$231K	0.11%	258

Other funds holding BIB

HCM

Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

OPS

Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UMC

United Maritime Capital New York $15.2M AUM 45.42% 1-Year Est. Return

Two Sigma Securities's BIB Position: Q3 2021 in Review

Two Sigma Securities sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2021, closing a stake of 2,461 shares — an estimated $243K sold.

Two Sigma Securities first reported a position in BIB in Q2 2016 and held it in 3 quarters. The position peaked at $297K in Q2 2017. 32 funds tracked by Wall St. Rank hold BIB as of Q3 2021.

Two Sigma Securities reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2021 after selling out during the quarter.
Two Sigma Securities sold 2,461 ProShares Ultra NASDAQ Biotechnology shares in Q3 2021, an estimated $243K.
Two Sigma Securities first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2016 and held it in 3 quarters.
Two Sigma Securities's ProShares Ultra NASDAQ Biotechnology position peaked at $297K in Q2 2017.
32 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2021.

Based on Two Sigma Securities's 13F filing for Q3 2021, filed 15 Nov 2021.